MedTrace Logo

Cytomegalovirus-Specific Response Measured by QuantiFeron® and Overall Immunologic Response Measured by ImmuKnow® in Lung Transplant Patients CMV-positive

NCT02076971 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 92

Last updated 2016-09-14

No results posted yet for this study

Summary

The purpose of this study is to determine the sensitivity and specificity of QuantiFeron® and ImmuKnow® in combination for early detection of patients who will develop CMV infection in lung transplant patients with CMV-positive serology (R+) prior to transplant.

Conditions

  • Cytomegalovirus Infections

Sponsors & Collaborators

  • Roche Farma, S.A

    collaborator INDUSTRY

  • Fundacio Catalana de Pneumologia

    lead OTHER

Principal Investigators

  • Victor Monforte, MD · Hospital Vall d'Hebron

  • Piedad Ussetti, MD · Hospital Puerta de Hierro

  • Susana Gómez, MD · Hospital Vall d'Hebron Laboratory

  • Victor Monforte, MD · Hospital Vall d'Hebrón

  • Piedad Ussetti, MD · Hospital Puerta Hierro

  • Francisco Santos, MD · Hospital Reina Sofía

  • José Cifrián, MD · Hospital Marqués de Valdecilla

  • José M Borro, MD · Hospital Universitario A Coruña

  • Virginia Pérez, MD · Hospital 12 de Octubre

  • Amparo Solé, MD · Hospital Universitario La Fe

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02076971 on ClinicalTrials.gov